Aspen Neuroscience presented at the 2024 ISCT annual meeting in Vancouver.

The presentation focused on their autologous iPSC-derived neuron replacement therapy for Parkinson's disease, ANPD001.

Executives discussed advancements in research, manufacturing, and analytical development strategies for ANPD001.

Key topics included manufacturing considerations, iPSC-derived cell therapy characterization, and analytical development strategies.

Aspen's platform integrates cell biology, machine learning, and genomic approaches to create personalized therapies.

The company aims to address diseases with high unmet medical needs, starting with Parkinson's disease.

Their goal is to translate cell and gene therapies into safe and effective medicines to improve patients' lives.